Sight Sciences Q2 Revenue Beats, Raises 2026 Guidance
SGHT sits 84% above its 52-week low of $3.19 on elevated volume (2.3× avg).
Summary
Sight Sciences delivered a strong Q2: revenue rose 20% to $23.4M, beating the $21.68M consensus, while net loss narrowed 63% to $4.4M. Gross margin held at 91%, and operating expenses fell 11% on lower personnel costs. Management raised full-year revenue guidance to $88M-$92M (from $83M-$89M) and cut adjusted opex guidance to $92M-$94M. This follows the recent FDA clearance for the OMNI Ultra Surgical System, adding a growth catalyst. The beat and guidance raise signal accelerating commercial momentum across both glaucoma and dry eye segments.
At the time of this announcement, SGHT was trading at $5.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302M. The 52-week trading range was $3.19 to $9.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.